← 返回首页
亚洲 · 区域市场 · Business Standard

Piramal Pharma soars 15% in weak market on huge volume post Q2 results

来源:Business Standard · 印度 1 小时前

With H2 typically stronger than H1, Piramal Pharma's management said it is well-positioned to deliver a strong FY performance, supported by healthy order book and encouraging…

在 Business Standard 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.business-standard.com)

推荐阅读